JP2021532123A5 - - Google Patents

Info

Publication number
JP2021532123A5
JP2021532123A5 JP2021503750A JP2021503750A JP2021532123A5 JP 2021532123 A5 JP2021532123 A5 JP 2021532123A5 JP 2021503750 A JP2021503750 A JP 2021503750A JP 2021503750 A JP2021503750 A JP 2021503750A JP 2021532123 A5 JP2021532123 A5 JP 2021532123A5
Authority
JP
Japan
Prior art keywords
optionally substituted
group
metal complex
pharmaceutically acceptable
hydrate
Prior art date
Application number
JP2021503750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532123A (ja
JPWO2020023247A5 (https=
JP7395194B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042025 external-priority patent/WO2020023247A1/en
Publication of JP2021532123A publication Critical patent/JP2021532123A/ja
Publication of JPWO2020023247A5 publication Critical patent/JPWO2020023247A5/ja
Publication of JP2021532123A5 publication Critical patent/JP2021532123A5/ja
Application granted granted Critical
Publication of JP7395194B2 publication Critical patent/JP7395194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021503750A 2018-07-23 2019-07-16 外因性および内因性アルブミンを放射性標識するためのイメージング剤 Active JP7395194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702081P 2018-07-23 2018-07-23
US62/702,081 2018-07-23
PCT/US2019/042025 WO2020023247A1 (en) 2018-07-23 2019-07-16 Imaging agents for radiolabeling exogenous and endogenous albumin

Publications (4)

Publication Number Publication Date
JP2021532123A JP2021532123A (ja) 2021-11-25
JPWO2020023247A5 JPWO2020023247A5 (https=) 2022-07-26
JP2021532123A5 true JP2021532123A5 (https=) 2022-07-26
JP7395194B2 JP7395194B2 (ja) 2023-12-11

Family

ID=69181921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503750A Active JP7395194B2 (ja) 2018-07-23 2019-07-16 外因性および内因性アルブミンを放射性標識するためのイメージング剤

Country Status (11)

Country Link
US (1) US20210353783A1 (https=)
EP (1) EP3826685A4 (https=)
JP (1) JP7395194B2 (https=)
KR (1) KR20210035213A (https=)
CN (1) CN112823028A (https=)
AU (1) AU2019309242B2 (https=)
BR (1) BR112021001314A2 (https=)
CA (1) CA3107328A1 (https=)
IL (1) IL280308B2 (https=)
MX (1) MX2021000926A (https=)
WO (1) WO2020023247A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3263646A1 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US20050233307A1 (en) * 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
US20040208828A1 (en) * 2003-02-04 2004-10-21 Lutz Lehmann Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
KR100695744B1 (ko) * 2005-05-03 2007-03-19 한국원자력연구소 디티피에이(dtpa) 유도체 및 이들을 이용한 금속 착화물, 이들을 포함하는 방사선원 및 조영제
WO2008070384A2 (en) * 2006-11-06 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of preparing macromolecular contrast agents and uses thereof
FR2909881A1 (fr) * 2006-12-14 2008-06-20 Inst Nat Sante Rech Med Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation
EP2630971B8 (en) * 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems

Similar Documents

Publication Publication Date Title
Hermanek et al. TNM supplement 1993: a commentary on uniform use
JP2020508302A5 (https=)
JP2021534168A5 (https=)
ES2959419T3 (es) Formulaciones secas por aspersión
ES2670852T3 (es) Colorantes con policiclo y uso de los mismos
AU2006270566B2 (en) Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
JP2021505541A5 (https=)
JP2021534158A5 (https=)
JP2021532123A5 (https=)
KR20220066098A (ko) 섬유모세포 활성화 단백질 (fap)-표적화 영상화 및 암 및 다른 섬유화 및 염증성 질환의 요법
JP7184775B2 (ja) 黄体化ホルモン放出ホルモン受容体(lhrh-r)コンジュゲートおよびその使用
JP2020514278A5 (https=)
ES2970618T3 (es) Profármacos de derivados de auristatina E que se unen a la albúmina
JP5106397B2 (ja) 生体適合性n,n−二置換スルホンアミド含有蛍光色素標識
JP2018062523A5 (https=)
EP2920186A1 (en) Novel gold(iii) complexes containing n-heterocyclic carbene ligand, synthesis, and their applications in cancer treatment and thiol detection
CN113453721A (zh) Metap2抑制剂的生物标志物及其应用
JP2017530129A (ja) ツブリシン複合体を用いた癌の治療方法
Wu et al. Met-targeted dual-modal MRI/NIR II imaging for specific recognition of head and neck squamous cell carcinoma
JP2006515836A5 (https=)
CN113209315A (zh) 靶向肿瘤的多肽探针及应用
JP2020531509A (ja) 炭酸脱水酵素陽性がんを標的とするfbsa系治療および放射性造影複合体
JP2021505551A (ja) メイタンシノイド系薬物送達システム
JPWO2020023247A5 (https=)
EP4139402A1 (en) Sterically shielded heptamethine cyanine dyes